Post-transplant lymphoproliferative disorders: From epidemiology to pathogenesis-driven treatment
Open Access
- 1 December 2015
- journal article
- review article
- Published by Elsevier BV in Cancer Letters
- Vol. 369 (1), 37-44
- https://doi.org/10.1016/j.canlet.2015.08.007
Abstract
No abstract availableKeywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (IG-14258, IG-13233)
This publication has 82 references indexed in Scilit:
- Molecular Pathogenesis of B-Cell Posttransplant Lymphoproliferative Disorder: What Do We Know So Far?Journal of Immunology Research, 2013
- Spectrum of Cancer Risk Among US Solid Organ Transplant RecipientsJama-Journal Of The American Medical Association, 2011
- B-Cell Stimulatory Cytokines and Markers of Immune Activation Are Elevated Several Years Prior to the Diagnosis of Systemic AIDS–Associated Non-Hodgkin B-Cell LymphomaCancer Epidemiology, Biomarkers & Prevention, 2011
- Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphomaBlood, 2011
- Cancer biomarkers in HIV patientsCurrent Opinion in HIV and AIDS, 2010
- Risk factors for early‐onset and late‐onset post‐transplant lymphoproliferative disorder in kidney recipients in the United StatesAmerican Journal of Hematology, 2010
- Viral Response to Chemotherapy in Endemic Burkitt LymphomaClinical Cancer Research, 2010
- How I treat EBV lymphoproliferationBlood, 2009
- Latent Membrane Protein 1 of Epstein-Barr Virus Activates the hTERT Promoter and Enhances Telomerase Activity in B LymphocytesJournal of Virology, 2008
- A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus–associated lymphoid malignanciesBlood, 2006